Or­biMed dou­bling down on Asia biotech bets with $450M fund

Over the last nine years Or­biMed has gath­ered more than a half bil­lion dol­lars ear­marked for its Asia group’s life sci­ences in­vest­ments. And now it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.